Extended Data Fig. 4: Sirpα deficiency suppresses tumor growth and Sirpα is associated with poor patient prognosis.
a. Survival analysis of WT mice (n = 12 mice) and Sirpa-/- mice (n = 13 mice) that bearing subcutaneous LLC tumor. b. Survival analysis of WT mice (n = 7 mice) and Sirpa-/- mice (n = 7 mice) that bearing subcutaneous Hepa1-6 tumor. c, e, g. The overall survival in patients with SIRPAhigh and SIPRAlow in colon cancer (GSE17536 and GSE17537, n = 232) (c), lung squamous carcinoma (TCGA-LUSC, n = 493) (e) and liver cancer (TCGA-LIHC, n = 365) (g). d, f, h. The disease-free survival in patients with SIRPAhigh and SIPRAlow in colon cancer (GSE17536 and GSE17537, n = 187) (d), lung squamous carcinoma (TCGA-LUSC, n = 476) (f) or liver cancer (TCGA-LIHC, n = 359) (h). i-j. Change of body weight (i) and disease activity index (j) for colitis of WT mice (n = 7 mice) and Sirpa-/- mice (n = 7 mice) during DSS induction. Disease activity index was calculated by summing the scores for body weight loss. k. The expression level of CD47 in MC38-Vector and MC38-CD47-/- cells in basal and inflammatory conditions (n = 3 independent experiments). l. The growths of MC38 tumors in WT mice without treatment (Ctrl; n = 6 mice), WT mice treated with anti-CD47 (n = 6 mice), WT mice treated with Sirpa-ED-FC protein (n = 6 mice) and Sirpa-/- mice without treatment (n = 9 mice). Data are pooled from 2 independent experiments (a), 3 independent experiments (k) or from one representative of five independent experiments(b), and from one independent experiment (i, j, l). P values (a-h) were performed with the log-rank test. P values (i, j, l) were used unpaired Student’s two-tailed t-test, and P values (k) were used ratio paired Student’s two-tailed t-test. Error bars show mean ± s.e.m.
